293 related articles for article (PubMed ID: 21154590)
21. Biological diagnosis for neuroblastoma using the combination of highly sensitive analysis of prognostic factors.
Tajiri T; Tanaka S; Higashi M; Kinoshita Y; Takahashi Y; Tatsuta K; Suita S
J Pediatr Surg; 2006 Mar; 41(3):560-6. PubMed ID: 16516635
[TBL] [Abstract][Full Text] [Related]
22. Association among EPHB2, TrkA, and MYCN expression in low-stage neuroblastomas.
Tang XX; Evans AE; Zhao H; Cnaan A; Brodeur GM; Ikegaki N
Med Pediatr Oncol; 2001 Jan; 36(1):80-2. PubMed ID: 11464911
[TBL] [Abstract][Full Text] [Related]
23. Dissection of the oncogenic MYCN transcriptional network reveals a large set of clinically relevant cell cycle genes as drivers of neuroblastoma tumorigenesis.
Murphy DM; Buckley PG; Bryan K; Watters KM; Koster J; van Sluis P; Molenaar J; Versteeg R; Stallings RL
Mol Carcinog; 2011 Jun; 50(6):403-11. PubMed ID: 21557326
[TBL] [Abstract][Full Text] [Related]
24. Expression of mRNA for the neurotrophin receptor trkC in neuroblastomas with favourable tumour stage and good prognosis.
Rydén M; Sehgal R; Dominici C; Schilling FH; Ibáñez CF; Kogner P
Br J Cancer; 1996 Sep; 74(5):773-9. PubMed ID: 8795581
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification.
Asgharzadeh S; Pique-Regi R; Sposto R; Wang H; Yang Y; Shimada H; Matthay K; Buckley J; Ortega A; Seeger RC
J Natl Cancer Inst; 2006 Sep; 98(17):1193-203. PubMed ID: 16954472
[TBL] [Abstract][Full Text] [Related]
26. MYCN RNA levels determined by quantitative in situ hybridization is better than MYCN gene dosages in predicting the prognosis of neuroblastoma patients.
Chang HH; Tseng YF; Lu MY; Yang YL; Chou SW; Lin DT; Lin KH; Jou ST; Hsu WM; Jeng YM
Mod Pathol; 2020 Apr; 33(4):531-540. PubMed ID: 31695155
[TBL] [Abstract][Full Text] [Related]
27. Minimal residual disease in peripheral blood stem cell harvests from high-risk neuroblastoma patients.
Avigad S; Feinberg-Gorenshtein G; Luria D; Jeison M; Stein J; Grunshpan A; Sverdlov Y; Ash S; Yaniv I
J Pediatr Hematol Oncol; 2009 Jan; 31(1):22-6. PubMed ID: 19125082
[TBL] [Abstract][Full Text] [Related]
28. Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma.
Haber M; Smith J; Bordow SB; Flemming C; Cohn SL; London WB; Marshall GM; Norris MD
J Clin Oncol; 2006 Apr; 24(10):1546-53. PubMed ID: 16575006
[TBL] [Abstract][Full Text] [Related]
29. Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group.
Schneiderman J; London WB; Brodeur GM; Castleberry RP; Look AT; Cohn SL
J Clin Oncol; 2008 Feb; 26(6):913-8. PubMed ID: 18281664
[TBL] [Abstract][Full Text] [Related]
30. Reevaluation of trkA expression as a biological marker of neuroblastoma by high-sensitivity expression analysis--a study of 106 primary neuroblastomas treated in a single institute.
Hishiki T; Saito T; Terui K; Sato Y; Takenouchi A; Yahata E; Ono S; Nakagawara A; Kamijo T; Nakamura Y; Matsunaga T; Yoshida H
J Pediatr Surg; 2010 Dec; 45(12):2293-8. PubMed ID: 21129533
[TBL] [Abstract][Full Text] [Related]
31. Expression of inhibitor-of-apoptosis protein (IAP) livin by neuroblastoma cells: correlation with prognostic factors and outcome.
Kim DK; Alvarado CS; Abramowsky CR; Gu L; Zhou M; Soe MM; Sullivan K; George B; Schemankewitz E; Findley HW
Pediatr Dev Pathol; 2005; 8(6):621-9. PubMed ID: 16328668
[TBL] [Abstract][Full Text] [Related]
32. Co-amplification of MYCN and a DEAD box gene (DDX1) in primary neuroblastoma.
Squire JA; Thorner PS; Weitzman S; Maggi JD; Dirks P; Doyle J; Hale M; Godbout R
Oncogene; 1995 Apr; 10(7):1417-22. PubMed ID: 7731693
[TBL] [Abstract][Full Text] [Related]
33. Pilot study to evaluate MYCN expression as a neuroblastoma cell marker to detect minimal residual disease by RT-PCR.
Wagner LM; Burger RA; Guichard SM; Raimondi SC; Santana VM; Furman WL; Barnette P; Danks MK
J Pediatr Hematol Oncol; 2006 Oct; 28(10):635-41. PubMed ID: 17023822
[TBL] [Abstract][Full Text] [Related]
34. Expression of B-myb in neuroblastoma tumors is a poor prognostic factor independent from MYCN amplification.
Raschellà G; Cesi V; Amendola R; Negroni A; Tanno B; Altavista P; Tonini GP; De Bernardi B; Calabretta B
Cancer Res; 1999 Jul; 59(14):3365-8. PubMed ID: 10416595
[TBL] [Abstract][Full Text] [Related]
35. Regulation of MYCN expression in human neuroblastoma cells.
Jacobs JF; van Bokhoven H; van Leeuwen FN; Hulsbergen-van de Kaa CA; de Vries IJ; Adema GJ; Hoogerbrugge PM; de Brouwer AP
BMC Cancer; 2009 Jul; 9():239. PubMed ID: 19615087
[TBL] [Abstract][Full Text] [Related]
36. IGF2BP1 harbors prognostic significance by gene gain and diverse expression in neuroblastoma.
Bell JL; Turlapati R; Liu T; Schulte JH; Hüttelmaier S
J Clin Oncol; 2015 Apr; 33(11):1285-93. PubMed ID: 25753434
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of MYCN and ID2 overexpression in neuroblastoma.
Alaminos M; Gerald WL; Cheung NK
Pediatr Blood Cancer; 2005 Dec; 45(7):909-15. PubMed ID: 16047351
[TBL] [Abstract][Full Text] [Related]
38. High expression of the novel endothelin-converting enzyme genes, Nbla03145/ECEL1alpha and beta, is associated with favorable prognosis in human neuroblastomas.
Kawamoto T; Ohira M; Hamano S; Hori T; Nakagawara A
Int J Oncol; 2003 Apr; 22(4):815-22. PubMed ID: 12632073
[TBL] [Abstract][Full Text] [Related]
39. MicroRNA-149 is associated with clinical outcome in human neuroblastoma and modulates cancer cell proliferation through Rap1 independent of MYCN amplification.
Xu Y; Chen X; Lin L; Chen H; Yu S; Li D
Biochimie; 2017 Aug; 139():1-8. PubMed ID: 28456710
[TBL] [Abstract][Full Text] [Related]
40. Cross-study analysis of gene expression data for intermediate neuroblastoma identifies two biological subtypes.
Warnat P; Oberthuer A; Fischer M; Westermann F; Eils R; Brors B
BMC Cancer; 2007 May; 7():89. PubMed ID: 17531100
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
